MedTrace Logo

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2015-12-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.

Conditions

  • Stroke
  • Myocardial Infarctions

Interventions

DRUG

Clopidogrel

Clopidogrel 75 mg QD

DRUG

Aspirin 81 mg

Aspirin 81mg QD

DRUG

Aspirin >300 mg

Aspirin \>300 mg QD

Sponsors & Collaborators

Principal Investigators

  • Mark J Alberts, MD · Northwestern University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-04-30
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01586975 on ClinicalTrials.gov